True NorthHealth Labs Build
Compound Library

Peptide / GLP-1/GIP

Tirzepatide (Mounjaro / Zepbound)

Dual GLP-1 and GIP receptor agonist. Produces greater weight loss than semaglutide in head-to-head trials (SURMOUNT vs STEP). FDA-approved. Improves insulin sensitivity, reduces visceral fat, improves lipids. The most effective pharmaceutical weight loss agent available.

Build protocol outline Open dose calculator TNHL ebooks
Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.
Reference dose2.5mg SubQ weekly x4 → 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Slow titration essential.
Half-life120 hours
Risk flaglow
Regulatory noteFDA-approved context noted

Side effects and watch-outs

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Injection site reaction
  • Rare: pancreatitis
  • Rare: gallbladder disease
  • Muscle loss without resistance training
  • Rebound weight gain on cessation